Federal Register Notice: FDA is making available draft guidance for industry, Drug-Induced Liver Injury: Premarketing Clinical Evaluation. It is intended to assist the pharmaceutical industry and others engaged in new drug development in assessing a drug’s potential to cause severe drug-induced liver injury (one that is fatal or requires liver transplantation). To download this guidance, click here. To view this notice, click here.
